דילוג לתוכן הראשי
xMedica

NCT07685808ClinicalTrials.gov

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…

שלב 2דרושים 360 משתתפים22 אתריםמדינה אחת

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 360 participants (target), run at 22 sites.

How this score is built
  • Enrolment25/40

    360 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration6/10

    Planned over about 18 months

  • Sponsor scale9/10

    Regeneron Pharmaceuticals has led 250 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

מצבים רפואיים

  • Overweight or Obesity

זכאות

זכאות
מיןהכול
גילאים18 Years – ללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol Key Exclusion Criteria: 1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening 2. Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol 3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol 4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones 5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 2
הקצאהאקראי
מודל ההתערבותPARALLEL
מטרה ראשיתTREATMENT
הסתרהQUADRUPLE (4)
גיוסדרושים 360 משתתפים

נותן חסות ושותפים

  • Regeneron Pharmaceuticals נותן חסות

זרועות והתערבויות

  • Olatorepatide arm 1EXPERIMENTAL
  • Olatorepatide arm 2EXPERIMENTAL
  • Olatorepatide arm 3EXPERIMENTAL
  • Olatorepatide arm 4EXPERIMENTAL
  • Olatorepatide arm 5EXPERIMENTAL
  • Matching Placebo arm 6ACTIVE_COMPARATOR

התערבויות

  • תרופה Olatorepatide

    Administered per the protocol

  • תרופה Placebo

    Administered per the protocol

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    מסגרת זמן Up to approximately 60 weeks

  2. מדד תוצאה ראשוני

    Severity of TEAEs

    מסגרת זמן Up to approximately 60 weeks

  3. מדד תוצאה ראשוני

    Percent change in body weight

    מסגרת זמן From baseline to week 52

  4. מדד תוצאה משני

    Olatorepatide concentrations

    מסגרת זמן Up to approximately 60 weeks

  5. מדד תוצאה משני

    Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    מסגרת זמן Up to approximately 52 weeks

  6. מדד תוצאה משני

    Magnitude of ADA to olatorepatide

    מסגרת זמן Up to approximately 52 weeks

תאריכים

תאריכים
תאריך התחלה28 ביולי 2026 (בפועל)
סיום ראשוני21 בינואר 2028 (משוער)
סיום21 בינואר 2028 (משוער)
פורסם לראשונה6 ביולי 2026 (בפועל)
עודכן לאחרונה18 בנובמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהנובמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

22 אתרים מגייסים

United States

United States
מתקןעירמדינה או אזורמצב
Flourish Research, Ravenswood RheumatologyChicagoIllinoisמגייס
Charter Research LLC - ChicagoChicagoIllinoisמגייס
Alliance for Multispecialty Research (AMR) Clinical MiamiDoralFloridaמגייס
AMR Clinical - Fort MyersFort MyersFloridaמגייס
Tribe Clinical ResearchGreenvilleSouth Carolinaמגייס
AGA Clinical TrialsHialeahFloridaמגייס
Flourish Research, Nature Coast Clinical ResearchInvernessFloridaמגייס
Flourish Research, Jacksonville Center for Clinical ResearchJacksonvilleFloridaמגייס
AMR Clinical - LexingtonLexingtonKentuckyמגייס
K2 Medical Research Maitland LLC, Main OfficeMaitlandFloridaמגייס
AMR Clinical - MobileMobileAlabamaמגייס
NYC Research IncNew YorkNew Yorkמגייס
AMR Clinical - Chicago Oak BrookOak BrookIllinoisמגייס
Velocity Clinical Research - OmahaOmahaNebraskaמגייס
Rochester Clinical ResearchRochesterNew Yorkמגייס
Flourish Research, Legacy Oaks TowerSan AntonioTexasמגייס
The IMA Group, IMA Clinical Research St. PetersburgSt. PetersburgFloridaמגייס
Charter Research LLC - The VillagesThe VillagesFloridaמגייס
Diablo Clinical Research - Flourish ResearchWalnut CreekCaliforniaמגייס
Chase Medical ResearchWaterburyConnecticutמגייס
AMR Clinical WichitaWichitaKansasמגייס
Clinical Site Partners, LLC DBA Flourish ResearchWinter ParkFloridaמגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 18 בנובמבר 2026

    אתר נוסף

    1 site added (22 total)

    2122

  2. 13 באוקטובר 2026

    אתר נוסף

    3 sites added (21 total)

    1821

  3. 29 בספטמבר 2026

    אתר נוסף

    13 sites added (18 total)

    518

  4. 20 באוגוסט 2026

    המצב השתנה

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 20 באוגוסט 2026

    הגיוס נפתח

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 20 באוגוסט 2026

    אתר נוסף

    5 sites added (5 total)

    05